JAZZNasdaqPharmaceutical Preparations

Jazz Pharmaceuticals plc

234.57

−0.09 · −0.04%

post 227.72 −2.92%

Closed15:59 ET

Open235.35Volume670,559Mkt cap$14.6BP/E63.61EPS3.58

Day227.70 – 235.350%52-wk128.80 – 266.3872%

JAZZ

Jazz Pharmaceuticals plc

OpenVolumeMkt capP/EEPSDiv yield

Day – 52-wk –

Expected move

Inputs

±8.7%implied · straddle

207.60247.04

spot 227.32exp Jan 15ATM strike 230ATM straddle 23.20IV 29%

Nov 5 closeprovisional

Expected move

Inputs

Next report

Jan 11

before open · in 67 days

est.Q4 FY26

Earnings

Next report

Last report

+7.13%

vs ±7.9% implied · ×0.91

shaded = implied · ▲▼ = realized

Nov 2 '26 · confirmed

History

Largest filed tie

—

Supply chain

13F top-10 QoQ

+10.50%

shares held · 10 largest managers

13F · Jun 30 '26129d lag

650 managers

Top fund weight

0.41%

JAZZ weight · MDY

N-PORTJun 30 '26

4 funds

Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied

12 direct · 12 supply chain

JAZZ news

10-Q3dJazz Pharmaceuticals posts net loss of $483.4 million for Q3; nine-month net income $2.5 millionJAZZ—SEC

8-K3dJazz Pharmaceuticals posts 3Q26 revenue $1,243.0 million, GAAP net loss $483.4 millionJAZZ—SEC

8-K10dJazz Pharmaceuticals estimates $755 million IPR&D charge, $11.00 EPS hitJAZZ—SEC

8-K27dJazz PharmaceuticalsJAZZ—SEC

8-K43dJazz PharmaceuticalsJAZZ—SEC

49dJazz Pharmaceuticals (JAZZ) Places An $820M Epilepsy BetJAZZ—Yahoo Finance

Press releases·2 releases

press3dJazz Pharmaceuticals Announces Third Quarter 2026 Financial ResultsJAZZ—PR Newswire

press17dJazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026JAZZ—PR Newswire

Ages at 23:02 ET

Jazz Pharmaceuticals news

JAZZ news

Jazz Pharmaceuticals news

JAZZ news